ReviewCurrent medicinal chemistry2011
The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg).
Review in Current medicinal chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 76 citations in OpenAlex.
- Tumor hypoxia: Classification, detection, and its critical role in cancer progression.Biomolecules & biomedicine · 2025Review
- Total adenosine deaminase cases as an inflammatory biomarker of pleural effusion syndrome.World journal of clinical cases · 2025Article
- Immune microenvironment in papillary thyroid carcinoma: roles of immune cells and checkpoints in disease progression and therapeutic implications.Frontiers in immunology · 2024Review
- Extracellular adenosine induces hypersecretion of IL-17A by T-helper 17 cells through the adenosine A2a receptor.Brain, behavior, & immunity - health · 2022Article
- Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy.Pharmaceutics · 2022Review
- The Multifaceted Actions of CD73 During Development and Suppressive Actions of Regulatory T Cells.Frontiers in immunology · 2022Review
- Intratumoral regulatory T cells from colon cancer patients comprise several activated effector populations.BMC immunology · 2021Article
- A treatise on endothelial biology and exosomes: homage to Theresa Maria Listowska Whiteside.HNO · 2020Review
- Purinergic system as a potential target for inflammation and toxicity induced by thymol in immune cells and tissues.Molecular and cellular biochemistry · 2019Article
- Pro-inflammatory Effect of Downregulated CD73 Expression in EAE Astrocytes.Frontiers in cellular neuroscience · 2019Article
- CD39Oncotarget · 2018Article
- Purinergic signaling as potential target of thiamethoxam-induced neurotoxicity using silver catfish (Rhamdia quelen) as experimental model.Molecular and cellular biochemistry · 2018Article
- Purinergic signaling modulates the splenic inflammatory response in silver catfish naturally infected with Ichthyophthirius multifiliis.Parasitology research · 2018Article
- The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment.Contemporary oncology (Poznan, Poland) · 2018Review
- Mechanisms regulating immune surveillance of cellular stress in cancer.Cellular and molecular life sciences : CMLS · 2018Review
- Interaction between saliva's adenosine and tick parasitism: effects on feeding and reproduction.Parasites & vectors · 2017Article
- Barriers to Radiation-InducedFrontiers in immunology · 2017Review
- Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression.Purinergic signalling · 2016Review
- Immunomodulation of endothelial differentiated mesenchymal stromal cells: impact on T and NK cells.Immunology and cell biology · 2016Article
- Phenotypic and functional characteristics of CD39Oncoimmunology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Tumor-induced dysfunction of immune cells is a common problem in cancer. Tumors induce immune suppression by many different mechanisms, including accumulation of regulatory T cells (Treg). Adaptive Treg (Tr1) generated in the tumor microenvironment express CD39 and CD73 ectonucleotidases, produce adenosine and are COX2+PGE2+. Adenosine and PGE2 produced by Tr1 or tumor cells bind to their respective receptors on the surface of T effector cells (Teff) and cooperate in up-regulating cytosolic 3'5'-cAMP levels utilizing adenylyl cyclase isoform 7 (AC-7). In Teff, increased cAMP mediates suppression of anti-tumor functions. Treg, in contrast to Teff, seem to require high cAMP levels for mediating suppression. This differential requirement of Treg and Teff for cAMP offers an opportunity for pharmacologic interventions using selected inhibitors of the adenosine/PGE2 pathways. Blocking of adenosine/PGE2 production by Tr1 or blocking binding of these factors to their receptors on T cells or inhibition of cAMP synthesis in Teff all represent novel therapeutic strategies that used in combination with conventional therapies could restore anti-tumor functions of Teff . At the same time, these inhibitors could disarm Tr1 cells by depriving them of the factors promoting their generation and activity or by down-regulating 3'5'-cAMP levels. Thus, the pharmacologic control of Treg-Teff interactions offers a novel strategy for restoration of anti-tumor Teff functions and silencing of Treg. Used in conjunction with anti-cancer drugs or with immune therapies, this strategy has a potential to improve therapeutic effects by preventing or reversing tumor-induced immune suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.